Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines

Chronic spontaneous urticaria (CSU) negatively impacts patients ’ quality of life (QoL). The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) captures physical, psychosocial, and practical domains of QoL in CSU patients. The current analysis evaluated the effect of dupilumab on CU-Q2oL items in omalizumab-naïve CSU patients inadequately controlled wi th H1 antihistamines.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas Casale, Gil Yosipovitch, Sarbjit Saini, Moshe Ben-Shoshan, Lisa Beck, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research